In obese post-bariatric patients, blocking GLP-1 action using Exendin-9 reduced insulin secretion and the incidence of hypoglycemia (Jørgensen et al., 2013, Salehi et al., 2014), but corresponding data from mouse models have been conflicting. Here, GLP1R is linked to Hypoglycemia.